Absolutely. And the data seems to suggest starting Retts sufferers on Daybue earlier in life is better. So this could build considerably, just perhaps not as fast as some hoped. Either way if anyone is talking $40+ in the next year then that'll only be on the back of a takeover and no buyer will be as interested in Daybue as they are 2591.
NEU Price at posting:
$17.09 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)